HIGHLIGHTS
- who: BAY- and collaborators from the University of Rome Tor Vergata, Italy have published the research work: Identi fi cation and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells, in the Journal: (JOURNAL)
- what: The cell lines used in this study (ovarian adenocarcinoma SKOV-3, pancreatic adenocarcinoma HPAFII, breast adenocarcinoma MDA-MB231, acantholytic squamous cell carcinoma HCC 1806) were obtained from the American Type Culture Collection (ATCC). The authors show that blocking glucose uptake is synergistic with inhibition of SNAT2 demonstrating a balance between glycolysis and glutaminolysis . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.